Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers.

ABSTRACT:

Background

Carvedilol is commonly used to treat hypertension as a β- and α₁-adrenoreceptor blocker, but it is metabolized by CYP2D6, and CYP2D6^*10 allele is dominant in Asian population. The objective of this study was to assess the influence of CYP2D6 polymorphisms on the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of carvedilol in healthy Korean volunteers.

Methods

A PK/PD study for a single and multiple dosing of carvedilol were conducted. All volunteers in 3 genotypic groups received single oral dose of carvedilol 12.5 mg for 3 days, then 25 mg QD for 5 days, and 12.5 mg QD for another 3 days. PK parameters for carvedilol and its three metabolites were determined using non-compartmental analysis. For PD propert

SUBMITTER: Jung E 

PROVIDER: S-EPMC6021360 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature